Treating Parkinson’s disease patients with the experimental drug GM1 ganglioside improved symptoms and slowed their progression during a two and a half-year trial.
Treating Parkinson’s disease patients with the experimental drug GM1 ganglioside improved symptoms and slowed their progression during a two and a half-year trial.